Search Results - "Denkert C"

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.

Authors: Pusztai, L. Denkert, C. O'Shaughnessy, J. et al.

Source: Annals of Oncology. May2024, Vol. 35 Issue 5, p429-436. 8p.

585P HER2 IHC status of primary breast cancer tumor and brain metastases in the BMBC registry.

Authors: Laakmann, E. Denkert, C. Schmidt, M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS450-S450. 1p.

Expression of lysophosphatidic acid acyltransferase beta (LPAAT-ß) in ovarian carcinoma: correlation with tumour grading and prognosis.

Authors: Niesporek, S. Denkert, C. Weichert, W. et al.

Source: British Journal of Cancer. 5/9/2005, Vol. 92 Issue 9, p1729-1736. 8p.

Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.

Authors: Weichert, W. Denkert, C. Schmidt, M. et al.

Source: British Journal of Cancer. 2/23/2004, Vol. 90 Issue 4, p815-821. 7p.

Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆.

Authors: Denkert, C. Untch, M. Benz, S. et al.

Source: Annals of Oncology. Apr2021, Vol. 32 Issue 4, p500-511. 12p.

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.

Authors: Karn, T. Denkert, C. Weber, K.E. et al.

Source: Annals of Oncology. Sep2020, Vol. 31 Issue 9, p1216-1222. 7p.

Suppression of the reactive oxygen intermediates production of human macrophages by colorectal adenocarcinoma cell lines.

Authors: Siegert, A. Denkert, C. Leclere, A. et al.

Source: Immunology. Dec99, Vol. 98 Issue 4, p551-556. 6p. 4 Diagrams, 3 Charts.

Bewertung des Scherfestigkeitsverhältnisses für Schrauben festgelegter Festigkeitsklassen.

Authors: Dörre, M. Glienke, R. Denkert, C. et al.

Source: Materialwissenschaft und Werkstoffechnik; Apr2019, Vol. 50 Issue 4, p382-404, 23p

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILsWorking Group 2014

Authors: Salgado, R. Denkert, C. Demaria, S. et al.

Source: Annals of Oncology. Feb2015, Vol. 26 Issue 2, p259-271. 13p. 2 Color Photographs, 3 Charts.

α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.

Authors: Sinn, M Denkert, C Striefler, J K et al.

Source: British Journal of Cancer. 11/11/2014, Vol. 111 Issue 10, p1917-1923. 7p.

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial†.

Authors: Denkert, C. Loibl, S. Müller, B. M. et al.

Source: Annals of Oncology. Nov2013, Vol. 24 Issue 11, p2786-2793. 8p. 1 Diagram, 1 Chart, 3 Graphs.

RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.

Authors: Denkert, C. Loibl, S. Kronenwett, R. et al.

Source: Annals of Oncology. Mar2013, Vol. 24 Issue 3, p632-639. 8p. 1 Diagram, 1 Chart, 3 Graphs.

17P Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials.

Authors: Furlanetto, J. Denkert, C. Untch, M. et al.

Source: Annals of Oncology. 2021 Supplement 2, Vol. 32, pS27-S28. 2p.

The immunogenicity of breast cancer—molecular subtypes matter.

Authors: Denkert, C.¹

Source: Annals of Oncology. Aug2014, Vol. 25 Issue 8, p1453-1455. 3p.

Reply to Letter to the Editor "Final results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy—PENELOPE-B" by Sahin and Guven

Authors: Loibl, S. Nekljudova, V. Denkert, C.

Source: Annals of Oncology. Aug2025, Vol. 36 Issue 8, p1000-1001. 2p.

Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer.

Authors: Burstein, H.J. Curigliano, G. Gnant, M. et al.

Source: Annals of Oncology. Dec2025, Vol. 36 Issue 12, p1433-1446. 14p.

127O Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.

Authors: Karn, T. Denkert, C. Weber, K.E. et al.

Source: Annals of Oncology. 2020 Supplement 2, Vol. 31, pS58-S58. 1p.

9O Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling.

Authors: Karn, T Denkert, C Weber, K E et al.

Source: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.

25P Expression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial: Comparison of central immunohistochemistry with an automated cartridge-based system for mRNA assessment (on behalf of the GBG neoadjuvant and translational subboard).

Authors: Denkert, C Jank, P Link, T

Source: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.

364TiPAnti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97.

Authors: Decker, T Denkert, C Lübbe, K et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.